Emergent Biosolutions (EBS)DoD awarded $21.5M
DoD awarded Emergent Biosolutions a contract with $21.5M committed so far.
- $21.5M
- committed so far
- $66.9M
- maximum it could reach
- Signed
- Jan 8, 2026
- Updated
- Mar 4, 2026
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Nov 7, 2025Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On November 7, 2025, Louis W. Sullivan, M.D., a director of Emergent BioSolutions Inc. (the “Company”), notified the Company of his intent to retire as a Class II board member effective November 14, 2025.”
- Jan 8, 2026 · this disclosureFederal contract · $21.5M obligatedDepartment of Defense awarded Emergent BioSolutions Inc.: $21.5M obligated to date
What came next
- Feb 25, 2026Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On February 25, 2026, the Board of Directors (the “Board”) of Emergent BioSolutions Inc. (the “Company”) appointed John D. Fowler, Jr. as a Class II director effective March 1, 2026, with his initial term expiring at the Company’s 2026 annual meeting of stockholders.”
- Feb 26, 2026Company filing · Form 8-K · Results, Reg FDReported its results, and shared information with investors
- Apr 16, 2026Company filing · Form 8-K · Material agreement, Agreement endedSigned an important agreement, and ended an important agreement (and 2 more items)
- Apr 28, 2026Federal contract · $11K obligatedDepartment of Health and Human Services awarded Emergent BioSolutions Inc.: $11K obligated to date
- Apr 30, 2026Company filing · Form 8-K · Results, Reg FDReported its results, and shared information with investors
How to read USAspending.gov award record
The obligated amount is money the government has legally committed to pay and has set aside in its accounts. The ceiling, which USAspending calls the potential value, is the most the contract could be worth if every option is exercised and every possible order is placed. The ceiling is a limit, not a payment, and it is often many times the obligated amount.
Full guide: Contract ceiling vs obligated amount: the difference
What else is on file for Emergent Biosolutions
For Emergent Biosolutions, OQRO holds 3 insider filings (SEC Form 4 or Form 144) dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its EBS page.
How this filing works
Other disclosures at Emergent Biosolutions
- SEC Form 144Oct 7, 2026
- SEC Form 4Oct 7, 2026
- SEC Form 4Oct 5, 2026
- USAspending.gov award recordJun 4, 2026
- USAspending.gov award recordApr 28, 2026
- SEC Form 4Aug 18, 2025
Everything OQRO holds on this company is on its EBS page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO Pro is a paid subscription. You see the price before you pay
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
